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Abstract
Heparin and low molecular weight heparins have been demonstrated to reduce myocardial ischaemia/reperfusion (I/R) injury, although their
use is hampered by the risk of haemorrhagic and thrombotic complications. Chemical and enzymatic modifications of K5 polysaccharide have
shown the possibility of producing heparin-like compounds with low anticoagulant activity and strong anti-inflammatory effects. Using a rat
model of regional myocardial I/R, we investigated the effects of an epimerized N-,O-sulphated K5 polysaccharide derivative, K5-N,OSepi, on
infarct size and histological signs of myocardial injury caused by 30 min. ligature of the left anterior descending coronary artery followed by 1
or 24 h reperfusion. K5-N,OSepi (0.1–1 mg/kg given i.v. 15 min. before reperfusion) significantly reduced the extent of myocardial damage in a
dose-dependent manner. Furthermore, we investigated the potential mechanism(s) of the cardioprotective effect(s) afforded by K5-N,OSepi. In
left ventricular samples, I/R induced mast cell degranulation and a robust increase in lipid peroxidation, free radical-induced DNA damage and
calcium overload. Markers of neutrophil infiltration and activation were also induced by I/R in rat hearts, specifically myeloperoxidase activity,
intercellular-adhesion-molecule-1 expression, prostaglandin-E2 and tumour-necrosis-factor-a production. The robust increase in oxidative
stress and inflammatory markers was blunted by K5-N,OSepi, in a dose-dependent manner, with maximum at 1 mg/kg. Furthermore, K5-N,
OSepi administration attenuated the increase in caspase 3 activity, Bid and Bax activation and ameliorated the decrease in expression of Bcl-2
within the ischaemic myocardium. In conclusion, we demonstrate that the cardioprotective effect of the non-anticoagulant K5 derivative K5-N,
OSepi is secondary to a combination of anti-apoptotic and anti-inflammatory effects.
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Introduction
Ischaemia of the heart evokes a complex and inter-related sequence
of events resulting in myocardial dysfunction and damage. Although
reperfusion following transient ischaemia leads to restoration of
blood flow, there is compelling evidence to support the notion that
reperfusion may exacerbate the injury initially caused by ischaemia,
producing a so-called myocardial I/R injury [1]. Many lines of evi-
dence have convincingly shown that inflammatory response plays a
major role in determining the extension of myocardial damages
evoked by I/R [2]. After the restoration of blood flow, leucocytes
infiltrate into the myocardium and release cytokines, proteolytic
enzymes and reactive oxygen species (ROS) that significantly
contribute to the development of injuries [3]. Moreover, resident
mast cells also contribute to the myocardial dysfunction through the
release of superoxide [4] and other mediators, such as histamine
and leukotrienes, which favour neutrophil adhesion to the endothe-
lium [5]. The combination of multiple triggers, such as free radicals
production and calcium overload, has been reported to markedly
affect the outcomes of myocardial I/R injury [6]. Apoptosis has also
been implicated as a possible mechanism in the development of
myocardial infarction [7], and a significant increase in myocardial
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apoptosis have been documented in both animal models and
patients with ischaemic cardiomyopathy [8, 9]. Recently, a close
relationship between the temporal and spatial distribution of cyto-
kines in the infarcted myocardium and the detection of apoptosis
has been described in patients with myocardial infarction [10].
Therefore, interventions aimed at suppressing both post-ischaemic
inflammatory reaction and myocyte apoptosis may represent effec-
tive therapeutic strategies in the context of myocardial I/R injury.
Heparin and low molecular weight heparins (LMWH) have been
consistently demonstrated to reduce myocardial I/R injury [11, 12].
However, the major drawbacks of both heparin and LMWH still
remain their haemorrhagic and thrombotic complications [13].
Although heparin’s mechanism of action for myocardial protection
has been thought to be dependent on its anticoagulant property,
most recent findings suggest that an important contributor to the
cardioprotective effect of heparin involves suppression of the post-
ischaemic inflammatory response [14]. On this basis, considerable
efforts have been made to develop safer heparin derivatives with a
low anticoagulant activity and retaining strong anti-inflammatory
properties. In this study, we have investigated the effects of a semi-
synthetic, heparin-like derivative, K5-N,OSepi, obtained by combined
chemical and enzymatic modification of the Escherichia coli capsular
polysaccharide, in an in vivo experimental model of regional myocar-
dial I/R injury. The capsular polysaccharide of E. coli K5 bacteria can
be subjected to various degrees of chemical N-deacetylation/N-sul-
phation as well as O-sulphation, to yield different heparin-like semi-
synthetic polysaccharides [15]. Depending on their extent and
pattern of sulphation, chemically sulphated K5 derivatives have been
shown to possess different degree of antithrombotic/anticoagulant
activity. As previously described [16], the semi-synthetic glycosami-
noglycan K5 polysaccharide derivative K5-N,OSepi was obtained by
N-desacetylation/N, O-sulphation of K5 polysaccharide and epimer-
ization of K5 with the enzyme glucuronyl C5 epimerase. This
compound has been demonstrated to be endowed with anti-inflam-
matory and anti-adhesive effects, but it is devoid of any anti-coagu-
lant activity [16–18]. To date, the effects of this non-anticoagulant
heparin-like derivative on myocardial I/R injury have not yet been
investigated. Hence, this study was undertaken to extend the investi-
gation on K5-N,OSepi efficacy to conditions associate with myocar-
dial injury.
Materials and methods
Animals
A total of 108 male albino rats, Wistar strain, weighing 250–300 g
(Morini, Reggio Emilia, Italy) were quarantined for 7 days with labora-
tory chow (Rodentia, Bergamo, Italy) and water ad libitum. The experi-
mental protocol conformed to either the Guide for the Care and Use of
Laboratory Animals published by the United States National Institutes of
Health and the European Commission Directive 86/609/EEC and it was
approved by the Animal Care Committee of the University of Florence
(Italy).
Preparation and biochemical characterization of
the N-, O-sulphated K5 polysaccharide
The precursor of the compound K5-N,OSepi is the capsular K5 polysac-
charide obtained from E. coli strain 010:K5:H4, a polymer with the
structure [-4)-GlcA b1-4 GlcNAc-(1-]n in which the disaccharidic unit
formed by D-glucuronic acid and N-acetylglucosamine is linked by a a
1?4 bond. This structure is similar to N-acetylheparosan, the natural
precursory polymer of heparin. The purified K5 polysaccharide was pre-
pared as described by Urbinati et al. [19]. N, O-sulphated K5 polysac-
charide was obtained by chemical N- and O- sulphation of the K5
polysaccharide, followed by the enzymatic epimerization with glucuronyl
C5 epimerase, according to the method described by Gori et al. [16].
The epimerized product was purified by ultrafiltration, precipitated with
ethanol and passed through a cation-exchange resin. The O-sulphation
was performed by treating the product with tetrabutylamonium hydrox-
yde in N-N-dimetylformamide and with pyridine sulphur trioxide at 50°C
for 24 hrs. The product was finally depolymerized to the desired molec-
ular weight by controlled nitrous acid deamination. The structural profile
of the compound was characterized by nuclear magnetic resonance
(1H-NMR and 13C-NMR) analysis; the sulphate content was obtained
by sulphate/carboxyl ratio analysis and molecular weight determination
was performed by HPLC analysis as described [20]. The compound
used in these experiments had an average molecular weight of 6000 Da,
a sulphate/carboxyl ratio of 4.0 and an iduronic acid/glucuronic
acid ratio of 0.8. K5-N,OSepi was also tested for its antithrombotic/
anticoagulant activity, showing 8.96 ± 0.8 U/mg anti-factor Xa activity
by using a commercial photometric kit (COATEST Heparin; Cromogenix,
Bedford, MA, USA) and by following the protocol provided by the
manufacturer.
Surgical procedure and treatments
The rats were anaesthetized by intraperitoneal injection of sodium thio-
pental (50 mg/kg body weight; Abbott, Latina, Italy) and monitored for
body temperature, respiration pattern, loss of righting reflex, unrespon-
siveness and corneal reflexes. A cannula was inserted into the trachea
and the animals were ventilated with air by using a Palmer pump (U.
Basile, Comerio, Italy). Subcutaneous peripheral limb electrodes were
inserted and electrocardiogram (ECG) was continuously recorded for
the entire duration of the experiment. ECGs were analysed to determine
the incidence and duration of ventricular fibrillation (VF) and ventricular
tachycardia (VT). According to Gelvan et al. [21], VT was recognized as
three or more consecutive premature ventricular contractions and VF
was recognized as irregular modulating baseline. All rats underwent tho-
racotomy at the fifth left intercostal space, the pericardium was opened
and a loose 00 braided silk suture was placed around the left coronary
artery (LCA). Then, the chest was closed by a silk suture to minimize
heart displacement. Rats were allowed to equilibrate for 20 min. to
enable ECG values to stabilize. Ischaemia was induced by tightening the
threads of the coronary suture and was maintained for 30 min. Reper-
fusion was obtained by reopening the chest and cutting the ligature
around the coronary artery. The duration of reperfusion was pre-deter-
mined to 1 hr or 24 hrs.
Animals were randomly allocated into different groups (n = 12 per
group): sham group (rats underwent the same surgical procedures as
above, but without the tightening of the coronary sutures); I/R groups;
K5-N,OSepi groups (dose-range 0.1–1 mg/kg 15 min. before reperfusion)
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and B4/100 group (1 mg/kg 15 min. before reperfusion). B4/100 is a bio-
logically inactive non-sulphated polysaccharide compound used as nega-
tive control molecule.
Determination of area at risk and infarct size
At the end of reperfusion (1 hr or 24 hrs), LCA was re-tightened with a
00 braided silk suture in the same place of the previous ligature and
2 ml of Evans Blue (Sigma-Aldrich, St. Louis. MO, USA) was retro-
gradely injected with a thin catheter inserted into carotid artery to delin-
eate the in vivo area at risk (AAR) [22]. The chest was re-opened and
the hearts of the anaesthetized rats were quickly removed. To distin-
guish between viable ischaemic and infracted tissue, the p-nitro blue
tetrazolium (NBT) dye exclusion method was used. On removal, the
hearts were attached to a Langendorff’s apparatus through a cannula
introduced into the aorta and perfused with 10 ml of 1% NBT dissolved
in a modified Tyrode solution, at a constant pressure of 40 cm of water
at 37°C for 20 min. Following this treatment, the normal myocardium
shows an intense blue staining reaction because of the presence of
dehydrogenase enzymes, whereas ischaemia-reperfusion-injured lesions
remain unstained. Thus, the latter regions appear as clearly delineated,
unstained zones. The hearts were detached from the cannula, weighed,
fixed in buffered 4% formaldehyde for 12 hrs, and the ventricles sec-
tioned in 1-mm transverse slices from the apex to the ligature. In each
slice, the bound areas of the unstained area on the upside surface were
traced onto a superimposed acetate sheet and the encircled area was
measured by computer-assisted morphometry, as described below. The
left ventricular area, AAR, and the area of infarction for each slide were
then determined as previously described [22]. In each slice, the volume
of the damaged myocardium was calculated by multiplying the
unstained surface area for the thickness of the slice. The total volume
of the damaged myocardium was calculated as the sum of the partial
values of the different slices. To allow a comparison of the extension of
myocardial injury between hearts of different sizes, the total volume of
the damaged myocardium was divided by the heart weight (grams). All
measurements and calculations were performed by a single individual
(M.R.), who was blinded to treatment status.
Ultrastructural examination and tissue injury
scoring
Electron microscopic examination was carried out on ultrathin sections
of heart tissue fragments stained with uranyl acetate and alkaline bis-
muth subnitrate and examined under a JEM 1010 electron microscope
(Jeol, Tokyo, Japan) at 80 kV. In each fragment, two series of six to
eight ultrathin sections cut at two different levels were examined and
photographed. Myocyte and microvascular endothelium injury was
quantified from electron-micrographs (final magnifications range
910,000–920,000) as previously reported [23]. The criteria used are
reported in Table 1. Each animal was assigned a separate score for
myocyte and endothelial injury from two independent observers (D.B. &
A.P.), blinded to the experimental groups, and the values were then
averaged.
Table 1 Scoring method of myocyte and endothelial injury
Injury Score Degree of injury Description
Myocyte 0 Normal myocyte
1 Slight Mild intracellular oedema
Mild mitochondrial swelling
2 Moderate Mild intracellular oedema
Contracture of myofibrils
Marked mitochondrial swelling with clearing of matrix
Occasional focal clumping of mitochondrial cristae
Mild nuclear chromatin clumping
3 Severe Severe mitochondrial swelling with loss of cristae
Presence of intramitochondrial dense granules
Disarrangement of myofibrils
Plasma membrane rupture
Nuclear degeneration (apoptosis or karyolysis)
Endothelial 0 Normal endothelium
1 Slight Mild-to-moderate endothelial swelling
2 Moderate Marked endothelial swelling
Decreased pinocytotic vesicles
Mitochondrial swelling
3 Severe Severe mitochondrial swelling with loss of cristae
Plasma membrane rupture
Nuclear degeneration (apoptosis or karyolysis)
Neutrophil adhesion and extravasation
2198 ª 2012 The Authors
Journal of Cellular and Molecular Medicine ª 2012 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Evaluation of myeloperoxidase activity
MPO activity, which can be used as a marker for neutrophil accumula-
tion in tissues, was determined as previously described [23]. MPO
activity was defined as the quantity of enzyme degrading 1 lmol of per-
oxide per min. at 37°C and was expressed in mU/g of wet tissue.
Determination of prostaglandin E2 tumour
necrosis factor-a production
Prostaglandin E2 (PGE2) and tumour necrosis factor (TNF)-a were mea-
sured using commercial enzyme-linked immunosorbent assay (ELISA)
kits (Cayman Chemical, Ann Arbor, MI, USA), following the protocol
provided by the manufacturer and results are expressed as pg/ml.
Determination of thiobarbituric acid-reactive
substances
Thiobarbituric acid-reactive substances (TBARS) are end-products of
cell membrane lipid peroxidation by ROS and are considered reliable
marker of myocardial cell damage. TBARS were determined by mea-
surement of the chromogen obtained from the reaction of MDA with
2-thiobarbituric acid according to Aruoma et al. [24].
Evaluation of calcium content
The calcium content of the myocardial tissue was measured as
described previously [23] by using an atomic absorption spectropho-
tometer (Perkin-Elmer, Uberlingen, Germany) at a 422-nm wavelength.
The relevant values were determined by comparison with a standard
curve obtained with increasing concentrations of CaCl2 and expressed
as ng of calcium/mg of tissue (dry weight).
Computer-assisted morphometry
The surface areas of the I/R-injured myocardium on slices of hearts
stained with nitroblue tetrazoliurn were measured on the corresponding
profiles reported on the acetate sheets. These profiles were registered
through a CCTV television camera (Sony, Tokyo, Japan) interfaced with
an Apple Macintosh LC III personal computer through a Videospigot card
(Supermac, Sunnyvale, CA, USA). The software (Image Analysis Program
1.49, National Institute of Health, Bethesda, MD, USA) enables the areas
encircled by each profile to be measured. Evaluation of light transmit-
tance across mast cells was performed as previously described [23].
Determination of 8-hydroxy-2′-deoxyguanosine
DNA isolation from cardiac tissue homogenates was performed accord-
ing to Masini et al. [25]. Samples of DNA extract were used for 8-
hydroxy-2′-deoxyguanosine (8-OHdG) determination using a Bioxytech
enzyme immunoassay kit (Oxis, Portland, OR, USA), following the
instructions provided by the manufacturer. The values are expressed as
ng of 8OHdG per lg proteins.
Measurement of caspase-3 activity
The enzymatic activity of caspase-3 was determined using the Ac-Asp-
Glu-Val-Asp-AMC (Ac-DEVD-AMC; Bachem AG, Bubendorf, Switzerland)
fluorescent substrate [26]. Samples of myocardial tissues were homog-
enized and then centrifuged at 10,000 g for 10 min. The supernatants
were incubated with 40 lM of AC-DEVD-AMC for 60 min. at 37°C. Sub-
strate cleavage was monitored fluorimetrically (Spectrofluo JY3 D; Jobin
Yvon, Paris, France) at 380 nm excitation and 460 nm emission wave
lengths. Data are expressed as arbitrary units/mg proteins. One unit of
enzyme activity is defined as the amount of enzyme required to liberate
40 lmol of Ac-DEVD-AMC upon 60 min. at 37°C.
Western blot analysis
Western blots were carried out as previously described [27]. Proteins
were separated by 10% sodium dodecyl sulphate-polyacrylamide gel
electrophoresis and transferred to polyvinyldenedifluoride membranes.
The membranes were then incubated with primary and then secondary
antibodies and developed by using the ECL detection system. The
immunoreactive bands were visualized by autoradiography and the den-
sity of the bands was evaluated densitometrically by using Gel
Pro®Analyser 4.5, 2000 software (Media Cybernetics, Silver Spring,
MD, USA).
Statistical analysis
Data are expressed as mean ± SEM. One-way ANOVA followed by
Student–Newman–Keuls multiple comparison test or by Student’s t-test
for unpaired values was performed by using GraphPad Prism 4.02
(GraphPad Software, San Diego, CA, USA); P < 0.05 was considered
significant.
Materials
Unless stated otherwise, all compounds were purchased from the
Sigma-Aldrich Company Ltd. K5-N,OSepi was kindly provided by INAL-
CO RSM S.p.A (Montale, Pistoia, Italy). Goat polyclonal antibody against
ICAM-1, rabbit polyclonal antibodies against Bcl-2, Bid and Bax and
horseradish peroxidase-conjugated donkey anti-goat and anti-rabbit IgG
were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Luminol
ECL detection reagents were from Amersham (Buckinghamshire, UK).
Results
Effect of K5-N,OSepi on the infarct size caused
by regional myocardial I/R
The results of the computer-assisted morphometry on the I/R
hearts stained with nitroblue tetrazolium showed that administration
of K5-N,OSepi 15 min. before reperfusion induced a significant
reduction in the extension of myocardial damage in comparison
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with the non-treated rats at both 1 hr and 24 hrs (Fig. 1A). The
mean size of ischaemic lesions in the rats treated with K5-N,OSepi
was reduced in a dose-dependent manner at 1 hr reperfusion, with
a maximum effect at 1 mg/kg (50% reduction). The highest dose
of K5-N,OSepi evoked a similar 50% reduction in infarct volume
when measured after 24 hrs reperfusion.
The mean values for the area at risk (AAR) per left ventricle (LV)
ranged from 52 ± 6% to 59 ± 8% and were similar in all animal
groups, not modified by drug treatment (P > 0.05, data not shown).
When compared with sham-operated animals, 30-min. ischaemia
followed by 1- or 24-hr reperfusion caused a significant increase in
infarct size, expressed as per cent of AAR (57 ± 8% and 61 ± 3%,
respectively) (Fig. 1B). The portion of the AAR-rendered necrotic
was significantly reduced in the animals treated with K5-N,OSepi
(0.1–1 mg/kg) in a dose-dependent manner, reaching a maximum at
1 mg/kg. At this dose, infarct size was 20 ± 5% of the area at risk
after 1 hr reperfusion and 24 ± 4% of the area at risk after 24 hrs
reperfusion, approximately a 60% reduction in infarct size. In con-
trast, no tissue protection was found when rats were treated with
the polysaccharide B4/100 (1 mg/kg), used as negative control mol-
ecule.
Effect of regional myocardial I/R and K5-N,OSepi
on haemodynamic parameters and ECG analysis
The mean baseline values of MAP in all groups of animals ranged
from 117 ± 6 to 129 ± 7 mmHg, and were not significantly different
between groups (P > 0.05, Table 2). In sham-operated rats, infusion
of vehicle for K5-N,OSepi, 1 mg/kg, had no significant haemodynam-
ic effects. In rats subjected to coronary I/R, mean values for MAP
significantly decreased throughout the experimental period. When
compared with I/R-animals treated with vehicle, I/R-animals treated
with K5-N,OSepi or B4/100 did not exhibit any significant changes in
MAP (P > 0.05, Table 2). The mean baseline values for HR in all
groups of animals ranged from 427 ± 17 to 456 ± 11 bpm. In rats
subjected to coronary occlusion and reperfusion, there was no sig-
nificant alteration in HR in comparison with sham-operated animals
and drug treatment did not modify the mean values of HR. Examina-
tion of ECG recordings showed no ventricular arrhythmias in the
sham-operated animals, whereas 33% of the control rats subjected
to myocardial I/R injury had ventricular arrhythmias, which appeared
within the first 30 min. of reperfusion. K5-N,OSepi administration
evoked a significant dose-dependent recovery of myocardial func-
tion: VT and VF occurred in 25% of the animals treated with the low-
est dose of K5-N,OSepi (0.1 mg/kg) and in none of the animals
treated with the highest dose (1 mg/kg) (P < 0.01). Of note, K5-N,
OSepi (1 mg/kg) given to normal rats had no effects on HR (data
not shown).
K5-N,OSepi reduces the histological signs of
injury caused by I/R
When compared with normal left ventricular morphology of the
sham-operated rats (cardiomyocyte and endothelial cells, Fig. 2A
and E, respectively), the animals undergoing regional myocardial
ischaemia followed by 1 hr reperfusion showed the typical features
of myocardial and endothelial injury related to severe oxygen star-
vation and dysfunction. In particular, the cardiomyocytes showed
ultrastructural alterations, which ranged from intracellular oedema,
mitochondrial swelling and myofibril hypercontraction to plasma
membrane rupture and myofibril disarrangement (Fig. 2B and F).
The microvascular endothelium showed narrowed lumina (arrow)
and signs of cell injury, including cytoplasmic and mitochondrial
swelling and, in some instances, cell detachment and interstitial
haemorrhage (data not shown). In contrast, the left ventricular
myocardium from the rats subjected to I/R and treated with K5-N,
OSepi (1 mg/kg) showed a marked reduction in the ultrastructural
signs of injury, the most prominent changes being intracellular
oedema and myofibril hypercontraction in some cardiomyocytes
and moderate cytoplasmic swelling of the microvascular endothe-
lium (Fig. 2C and G). Of note, substitution of K5-N,OSepi with in-
active B4/100 resulted in ultrastructural signs of myocyte and
endothelial injury similar to the untreated I/R rats (Fig. 2E and H).
Semi-quantitative scoring performed on cardiomyocyte and endo-
thelial injury confirmed the visual observations and showed that
Fig. 1 Effects of K5-N,OSepi on myocardial infarct size evoked by regio-
nal I/R. (A) Dose–response effects of K5-N,OSepi (0.1–1 mg/kg) on the
extension of left ventricular myocardium with I/R-induced injury, as
evaluated on hearts stained with nitro-blue tetrazolium and (B) quantifi-
cation of infarct size after I/R injury, expressed as per cent of area at
risk (AAR), in the absence (vehicle) or presence of K5-N,OSepi (0.3–
1 mg/kg) or B4/100 (1 mg/kg). Data are means ± SEM of six animals/
group. *P < 0.01 versus vehicle (1 hr reperfusion) and •P < 0.01
versus vehicle (24 hrs reperfusion).
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Fig. 2 Histopathological examination of biopsies of left ventricular tissues. Representative electron micrographs of cardiomyocytes (upper panels)
and blood capillaries (lower panels) from: sham-operated rats (A, E), showing normal mitochondria and myofibrils and microvessels with open
lumina and normal organelle complement; rats undergoing 30 min. ischaemia followed by 60 min. reperfusion (B, F), showing mitochondrial swell-
ing (asterisk), severe myofibril hypercontraction and constriction of microvascular lumen (arrow); rats subjected to I/R and treated with 1 mg/kg
K5-N,OSepi (C, G), showing cytoplasmic oedema, moderate myofibril hypercontraction and nearly normal microvessels; rats subjected to I/R and
treated with 1 mg/kg B4/100 (D, H), showing similar myocyte and endothelial alteration as in the untreated I/R rats. Bars = 1 lm.
Table 2 Effect of vehicle, K5-N,OSepi or B4/100 on mean arterial pressure (MAP) and heart rate (HR) in sham-operated rats or ischaemic
reperfused rats
Group Baseline
Occlusion (min.) Reperfusion (min.)
15 30 30 60
Sham (n = 12)
MAP 128 ± 7 126 ± 4 119 ± 3 110 ± 6 112 ± 4
HR 427 ± 14 429 ± 16 426 ± 12 434 ± 16 429 ± 7
I/R Vehicle (n = 12)
MAP 129 ± 7 122 ± 5 115 ± 6 94 ± 7 95 ± 8
HR 454 ± 15 438 ± 13 438 ± 15 430 ± 2 434 ± 5
I/R + K5-N,OSepi 1 mg/kg (n = 12)
MAP 117 ± 6 109 ± 9 106 ± 10 97 ± 6 98 ± 9
HR 435 ± 39 440 ± 37 442 ± 38 422 ± 13 425 ± 24
I/R + B4/100 1 mg/kg (n = 12)
MAP 128 ± 8 120 ± 5 94 ± 8 88 ± 6 85 ± 7
HR 456 ± 11 432 ± 11 438 ± 12 430 ± 8 429 ± 13
All data are mean ± S.E.M. of n observations.
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K5-N,OSepi (1 mg/kg), but not B4/100, significantly blunts cardiac
cell damage (Fig. 3).
Effects of K5-N,OSepi on oxidative stress and
calcium overload induced by I/R injury
Rats that had undergone I/R exhibited a massive increase in tissue
markers of oxidative stress, such as TBARS production, an index of
peroxidation of cell membrane lipids and 8-OHdG, a marker of free
radical-induced DNA damage (Fig. 4A and B, respectively). The robust
increase in TBARS and 8-OHdG levels was blunted by K5-N,OSepi, in
a dose-dependent manner, with maximum effect at 1 mg/kg. Simi-
larly, I/R caused a 4-fold increase in calcium content in heart homo-
genates compared with sham-operated animals and this increase was
dose-dependently reduced by K5-N,OSepi (Fig. 4C). On the other
hand, administration of the inactive compound B4/100 (1 mg/kg) to
rats exposed to I/R had no significant effect on any of the measured
markers as compared with control rats that underwent I/R.
Effects of K5-N,OSepi on leucocyte infiltration
and activation
The improvement in the outcome of I/R injury was associated with a
reduced neutrophil infiltration measured in reperfused left ventricular
samples at both 1 hr and 24 hrs. As shown in Figure 5A, regional
myocardial I/R caused a robust increase in MPO activity, a specific
marker of local neutrophil activity, at 1 hr reperfusion, which further
increased after 24 hrs reperfusion. In K5-N,OSepi-treated animals,
the MPO activity was significantly reduced in a dose-dependent man-
ner, with maximum at 1 mg/kg in both the experimental conditions.
The adhesion molecule ICAM-1, which is the endothelial ligand for the
neutrophil receptor CD11b/CD18, was scarcely detectable in the
hearts from sham-operated animals and its expression was strongly
induced by 1 hr and 24 hrs reperfusion (Fig. 5B). Administration of
K5-N,OSepi drastically reduced the I/R-induced increase in ICAM-1
expression, without any significant differences between 1 hr and
24 hrs reperfusion. PGE2 and TNF-a, typical inflammatory prostanoid
and cytokine released by activated leucocytes, were significantly
increased in left ventricular tissue of I/R rats, as compared with the
Fig. 3 Semi-quantitative scoring of cardiomyocyte and endothelial cell
injury in the different groups. Injury scoring was measured subsequent to
I/R (30/60 min.) in the absence (vehicle) or presence of B4/100 (1 mg/kg)
or K5-N,OSepi (1 mg/kg) treatment. *P < 0.01 versus vehicle and B4/100.
Fig. 4 Dose–response effects of K5-N,OSepi on lipid peroxidation, free-
radical-induced DNA damage and calcium release in left ventricular tis-
sue. TBARS production (A), 8-OHdG levels (B) and calcium content (C)
were measured subsequent to sham operation (Sham) or I/R (30/
60 min.) in the absence (vehicle) or presence of K5-N,OSepi (0.1–
1 mg/kg) or B4/100 (1 mg/kg) treatment. Data are means ± S.E.M. of
eight animals/group. *P < 0.01 versus vehicle.
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sham-operated animals (Fig. 5C and D, respectively). In contrast,
administration of K5-N,OSepi, but not B4/100, prevented the I/R-
induced rise in PGE2 and TNF-a levels in a dose-dependent manner.
The maximal inhibitory effect recorded at 1 hr reperfusion was similar
to that recorded after 24 hrs reperfusion.
Effects of K5-N,OSepi on cardiac mast cells
Morphometric analysis of cardiac mast cells in the left ventricle
showed that light transmittance across mast cells, which is inversely
related to the amount of secretory granules, was significantly higher in
I/R hearts in comparison with the sham-operated ones (Fig. 6). Con-
versely, in the rats treated with K5-N,OSepi, but not with B4/100, the
light transmittance across cardiac mast cells was reduced in a dose-
dependent manner, reaching levels similar to those recorded in sham-
operated animals at the highest dose (1 mg/kg).
Effects of K5-N,OSepi on markers of apoptosis
When compared with sham-operated animals, there was a significant
increase in caspase-3 activity within the AAR obtained from rat hearts
subjected to myocardial I/R, which was significantly prevented by
K5-N,OSepi administration (Fig. 7A). Western blot analysis revealed
a significant reduction in the expression of the intact form of the
pro-apoptotic protein Bid in the rat hearts subjected to myocardial I/
R, when compared with sham-operated rats (Fig. 7B), thus demon-
strating its activation by cleavage of intact Bid into truncated forms
of Bid. The administration of K5-N,OSepi prevented the I/R-induced
activation of Bid, when compared with control rats. Accordingly, the
levels of the mitochondrial pro-apoptotic protein Bax were signifi-
cantly increased by I/R and reduced by K5-N,OSepi administration
(Fig. 7C). Interestingly, the basal expression of Bcl-2 protein, a well-
known suppressor of apoptosis, was significantly reduced in animals
Fig. 5 Effects of K5-N,OSepi on neutrophil infiltration and cytokines production induced by regional I/R. Myeloperoxidase (MPO) activity (A), ICAM-1
expression (B), PGE2 (C) and TNF-a (D) levels were measured in myocardial homogenates of sham-operated rats (Sham) and rats that underwent
30 min. ischaemia followed by 1 or 24 hr reperfusion (vehicle). K5-N,OSepi (0.1–1 mg/kg in panels (A, C and D) and 1 mg/kg in panel (B) or B4/
100 (1 mg/kg) were administered 15 min. before reperfusion. Densitometric analysis of the bands is expressed as relative optical density (O.D.) cor-
rected for the corresponding b-actin contents and normalized using the related sham-operated band. Data are means ± S.E.M. of eight animals/
group for MPO, PGE2 and TNF-a and three separate experiments for Western blot analysis. *P < 0.01 versus vehicle (1h reperfusion) and
•P < 0.01 versus vehicle (24 hrs reperfusion).
ª 2012 The Authors 2203
Journal of Cellular and Molecular Medicine ª 2012 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
J. Cell. Mol. Med. Vol 16, No 9, 2012
subjected to I/R in comparison with sham-operated rats and this
effect was attenuated by treatment with K5-N,OSepi (Fig. 7D). On
the contrary, all the above parameters were not changed by B4/100
treatment.
Overall, these results demonstrate that K5-N,OSepi beneficial
effects appear to involve a combination of anti-inflammatory and anti-
apoptotic mechanisms. Thus, targeting anti-inflammatory and
anti-apoptotic cascades, but not anticoagulant pathways, may hold
pharmacological potential for the therapeutic use of heparin-like
derivatives in the clinical setting of acute ischaemic events, with sig-
nificant reduction in the well-known haemorrhagic complications.
Discussion
At doses greatly exceeding those needed for anticoagulation, heparin
and low-molecular weight heparins substantially reduce myocardial
infarction [11, 12]. However, their potential for causing and haemor-
rhagic and thrombotic complications continues to arouse caution [13,
28]. Previous studies have revealed that heparin protection against
coronary occlusion is independent of the activity of heparin as an
anticoagulant and has been attributed largely to inhibition of comple-
ment [12] and neutrophil migration into I/R myocardium [29].
Accordingly, an O-desulphated non-anticoagulant high molecular
weight heparin has been recently demonstrated to attenuate myocar-
dial I/R injury in pigs and dogs [30, 31]. Here, for the first time, we
demonstrated that protective effects against myocardial infarction can
be obtained by using K5-N,OSepi, a new bacterial polysaccharide
derivative, structurally related to low molecular weight heparins, with
a very high degree of N- and O-sulphation and devoid of any anticoag-
ulant activity. This semi-synthetic glycosaminoglycan K5 derivative
was obtained through highly selective chemical and enzymatic modifi-
cations of the capsular K5 polysaccharide from E. coli. [15]. The pres-
ence of O-sulphated glucuronic acid residues, not detectable in
extractive heparin, and the conformational change induced by the
enzymatic modification of K5 by C5-epimerase enable its strong anti-
inflammatory activity, as shown in a rat model of carrageenan-
induced pleurisy [18] and in human LPS-stimulated mononuclear
cells [16]. Our group has also demonstrated that the K5 derivative
K5-N,OSepi protects the brain against I/R injury [17]. In this study,
we extend the understanding of the pharmacology of the heparin-like
compound, K5-N,OSepi, in a rat model of regional myocardial I/R
injury. Our results demonstrate that intravenous administration of K5-
N,OSepi 15 min. before the onset of reperfusion caused a significant
reduction in the degree of I/R-induced myocardial injury. The highest
dose of K5-N,OSepi used in this study (1 mg/kg) reduced myocardial
infarct size by approximately 60%, when evaluated at 1 hr reperfu-
sion, without affecting haemodynamic parameters. Interestingly,
quantitatively similar reduction in infarct size has been previously
reported in different animal models of ischaemic preconditioning,
which is recognized as one of the strongest forms of in vivo protec-
tion against myocardial I/R injury [32, 33]. In addition, we demon-
strated that a substantial reduction in the mean size of ischaemic
lesions was still detectable at 24 hrs reperfusion, thus further sup-
porting the clinical relevance of the present study. The persisting pro-
tective effects exerted by K5-N,OSepi administration can be, at least
in part, due to the high resistance to heparanase digestion, previously
documented for similar N-deacetylated/N-sulphated, C5epimerizated
K5 polysaccharide derivatives [34]. In contrast, the biologically inac-
tive non-sulphated polysaccharide B4/100, used as negative control
molecule, was ineffective in preventing myocardial injury at both 1 hr
and 24 hrs reperfusion. Our findings support previous studies show-
ing that, in the ischaemic myocardium, reperfusion accelerates
inflammation, which may cause further injury [35]. Here, we con-
firmed that neutrophil infiltration of previously ischaemic sections of
the heart was higher in animals exposed to I/R, when compared with
sham-operated animals. Most notably, administration of K5-N,OSepi
suppressed the expression of the adhesion molecule ICAM-1, and
thus significantly reduced neutrophil migration out of the vessels. In
addition, the elevated levels of MPO activity and PGE2 and TNF-a pro-
duction, used as markers of tissue leucocyte infiltration and activa-
tion, were inhibited by K5-N,OSepi treatment. These data are in
agreement with other reports showing that heparin and heparin-like
derivatives reduce neutrophil adhesion to I/R coronary and vascular
endothelium [30, 36]. We can thus speculate that the decreased myo-
cardial neutrophil infiltration may have significantly contributed to the
reduced heart injury in rats treated with K5-N,OSepi. As previous
studies have shown that prostacyclin (PGI2) plays an important role
in reducing neutrophil infiltration during myocardial infarction [37]
and defibrotide, an antithrombotic drug with no anticoagulant activity,
exert protective effects against myocardial I/R injury by increasing
PGI2 endothelial production [38], we may suppose that K5-N,OSepi
inhibits local leucocyte activation through an increase in PGI2 levels
in the damaged heart tissue. However, further study is required to
better elucidate the protective mechanism(s). The marked reduction
Fig. 6Mast cell densitometry evaluated as light transmittance across left
ventricular mast cells. Compared with sham-operated heart (Sham), the
I/R hearts (vehicle) show a significant increase in light transmittance,
indicating a decrease in intracellularly secretory granules, evaluated at
1 hr reperfusion. This effect is dose-dependently reverted by K5-N,OSepi
(0.1–1 mg/kg) treatment, but not by B4/100 (1 mg/kg). Data are
means ± S.E.M. of eight animals/group. *P < 0.01 versus vehicle.
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in the local inflammatory infiltrate caused by K5-N,OSepi treatment
may also account for the decrease in calcium overload and tissue
markers of oxidative stress, thus supporting the notion that release of
ROS from activated neutrophils is responsible at least in part for per-
oxidation of lipid membranes and free radical-induced DNA damage
in the myocardium. An additional contribution to the cardioprotection
evoked by the non-anticoagulant heparin-like derivative may rely on
its effects on cardiac mast cells. In fact, resident mast cells undergo
degranulation during post-ischaemic reoxygenation of the heart,
releasing powerful mediators, such as histamine, serotonin and
leukotrienes that can increase tissue oedema and induce cardiac
arrhythmias [39]. The reduced occurrence of cardiac arrhythmias in
the K5-N,OSepi-treated rats is probably related to the decrease in
mast cell histamine release, which can also account for the slight,
not-significant decrease in HR. In addition, Frangogiannis et al. [40]
have shown that in response to I/R, cardiac mast cells degranulate
and release TNF-a, which subsequently induces IL-6 expression in
infiltrating mononuclear cells. IL-6 in turn up-regulates myocardial
ICAM-1 expression, increasing susceptibility to neutrophil-induced
adhesion, extravasation and cytotoxicity [41]. Therefore, we may
speculate that the inhibitory effects of K5-N,OSepi on mast cell
degranulation contribute at least in part to the reduction in leucocyte
activation and infiltration and, hence, to myocardial salvage.
Complementary to the attenuation in the inflammatory response,
K5-N,OSepi further reduced myocardial apoptosis. After prolonged
ischaemia, cardiomyocyte cell death is attributable to necrosis,
whereas apoptosis occurs after short coronary occlusion and reperfu-
sion appears to accelerate the timing of apoptosis [42]. Cardiac-spe-
Fig. 7 Effects of K5-N,OSepi on markers of apoptosis in the hearts of rats that underwent myocardial I/R injury. Caspase 3 activity (A) and expres-
sion of the apoptotic markers Bid (B), Bax (C) and Bcl-2 (D) were measured in the hearts from sham-operated rats (Sham), rats subjected to 30-
min. myocardial ischaemia followed by 1-hr reperfusion (vehicle) or rats subjected to myocardial I/R and treated with K5-N,OSepi (1 mg/kg) or B4/
100 (1 mg/kg) treatment. Each immunoblot is from a single experiment and is representative of three separate experiments. Densitometric analysis
of the bands is expressed as relative optical density (O.D.) corrected for the corresponding b-actin contents and normalized using the related sham-
operated band. Data are means ± S.E.M. of four animals/group for caspase-3 activity and three separate experiments for Western blot analysis.
*P < 0.05 versus vehicle.
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cific overexpression of anti-apoptotic regulator Bcl-2 substantially
reduces infarct size, cardiac myocyte apoptosis and cardiac dys-
function following I/R [43]. Similarly, mice lacking the multi-
domain pro-apoptotic Bax demonstrate reductions in infarct size
and dysfunction following I/R [44], while activation of Bid (a pro-
apoptotic marker) into truncated forms of tBid has been shown to
operate during myocardial I/R [45]. In addition, several pharmaco-
logical interventions have been previously reported to exert protec-
tion in animal models of myocardial I/R injury, at least in part, by
affecting apoptotic cell death [46–48]. Our results indicate that
K5-N,OSepi mediated significant anti-apoptotic effects, which are
secondary to the prevention by K5-N,OSepi of Bax expression and
caspase 3 and Bid activation caused by I/R. In addition, K5-N,OSepi
ameliorated the expression of the anti-apoptotic marker Bcl-2 pro-
tein, whose levels were drastically reduced by I/R injury. Recently,
evidence has been accumulating to show that there is continual
cross-talk between local I/R-related inflammatory response and car-
diomyocyte apoptosis [49, 50]. For instance, in cardiomyocytes,
apoptotic cell death in response to TNF-a involves calcium-mediated
calpain activation [51]. TNF-a also activates the extrinsic death path-
way resulting in the recruitment and activation of caspase-3 [52].
We might thus speculate that suppression of apoptosis by K5-N,OS-
epi is a secondary event through its modulation of inflammatory
response parameters, mainly TNF-a production. Nevertheless, in the
absence of direct experimental data, we cannot rule out the possibil-
ity that K5-N,OSepi directly affect specific apoptotic pathways. Fur-
ther investigation is required to determine the mechanism(s) more
precisely.
Taken together, the above-described results indicate that K5-N,
OSepi protects against I/R-induced myocardial cell injury and cardiac
dysfunction via several different mechanisms, including inhibition of
leucocyte infiltration and modulation of the apoptosis evoked by
regional myocardial I/R in the rat. The results of this study offer good
perspectives for a novel therapeutic approach in the medical treat-
ment of myocardial infarction, based on the use of new heparin deriv-
atives, with low anticoagulant and high anti-inflammatory activities.
These heparin-like derivatives may have several advantages over hep-
arin and low-molecular-weight heparins, mainly less risk of haemor-
rhagic and thrombotic complications, thus, meeting some crucial
requirements for clinical use.
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